Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer

Bone Marrow Transplantation

Volumn 17, Issue 2, 1996, Pages 157-162

  Bitran, J D ^a,c   Samuels, B ^a   Klein, L ^a   Hanauer, S ^a   Johnson, L ^a   Martinec, J ^a   Harris, E ^a   Kempler, J ^a,b   White, W ^a  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Division of Hematology/Oncology   (United States)

Author keywords

Breast cancer; High dose chemotherapy; Progenitor cell support

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; MELPHALAN; MORPHINE; OCTREOTIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; AGED; ARTICLE; BLADDER DISEASE; BREAST CANCER; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; FOLLOW UP; HEART DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; LUNG TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE; TREATMENT FAILURE; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; LEUKOCYTE COUNT; LIFE TABLES; MELPHALAN; MIDDLE AGED; PALLIATIVE CARE; REMISSION INDUCTION; SURVIVAL ANALYSIS; THIOTEPA; TREATMENT OUTCOME;

EID: 0030062308     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Mick R, Begg CB. Antman K et al. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 1989; 13: 33-38.
2. Peters WP, Shpall EJ, Jones RB et al. High dose combination alkylating agents with bone marrow support at initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1375.
3. Vincent MD, Trevor J, Powles R et al. Late intensification with high dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol 1988; 21: 222-260.
4. Williams SF, Mick R, Desser R et al. High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-1830.
5. Dunphy F, Spitzer G, Budzar A et al. Treatment of estrogenreceptor-negative or hormonally refractory breast cancer with double high dose chemotherapy and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
6. Williams SF, Gilewski T, Mick R et al. High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
7. Antman K, Ayash L, Elias A et al. A phase II study of high dose cyclophosphamide. thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1992; 10: 102-110.
8. Kennedy MJ, Beveridge RA, Rowley SD et al. High dose chemotherapy with reinfusion of purged autologous bone marrow following dose intensive induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-926.
9. Ghalie R, Richman CM, Adler SS et al. Treatment of metastatic breast cancer with a split course high dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol 1994; 12: 342-346.
10. Skipper HE. Combination therapy: some concepts and results. Cancer Chemother Rep 1974; 4: 137-145.
11. Frei E, Cucchi C, Rosowsky A et al. Alkylating agent resistance: in vitro studies of human cell lines. Proc Natl Acad Sci USA 1985; 82: 2158-2162.
12. Teicher B, Cucchi C, Lee J et al. Alkylating agents: in vitro studies of cases - resistance patterns in human tumor cell line. Cancer Res 1986; 46: 4379-4383.
13. Teicher B, Holden S. Cucchi C et al. Combination of N′, N′, N″ triethylenethiophosphoramide and cyclophosphamide in vitro and vivo. Cancer Res 1988; 48: 94-100.
14. Grad G, Lane N, Zimmerman T el al. High dose chemotherapy and autologous stem cell support in metastatic breast cancer: the University of Chicago experience. Proc Am Soc Clin Oncol 1994; 13: 73.
15. Bergsager DE. Treatment of plasma cell myeloma with cytotoxic agents. Arch Intern Med 1975; 135: 172-176.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Jones RB, Shpall EJ, Shogan J el al. The Duke AFM program: intensive induction chemotherapy for metastatic breast cancer. Cancer 1990; 66: 431-436.
18. Ayash L, Elias A, Wheeler C el al. Double dose intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.